Only if you know them can you beat
We offer our customers a valuable platform of microbiological capabilities ranging from the very early phases (HTS screening by phenotypic screening) to the selection of the clinical candidates by applying translational-based modelling based on PK/PD readout, through bacterial target validation.In addition to being proprietary of a Bacterial Culture Collections of clinical isolates, we can profile in vitro and in vivo new chemical entities (NCEs) against bacterial infections. Specifically-engineered isogenic strains are available for evaluating the role played by membrane permeability and can be used both for HTS purposes (phenotypic screen) and for understanding the mode by the macromolecule synthesis assay (MMS) available for ESKAPE pathogens.
Specific assays aimed to evaluate biofilm formation, expression of virulence factors, effect of specific treatment on bacterial population of persisters, bacterial fitness, inhibitory effect of new compounds on specific bacterial enzymes (e.g. Surface Plasmon Resonance with IMP, NDM, and VIM metallo-ß-lactamases) have been developed.
A full set of animal models of bacterial infections in rodents permits an in-depth evaluation of the efficacy of new antibacterial therapies and of translatability to human by coupling the PK and PD properties of compounds. Imaging techniques are consistently applied to different models thanks to the use of bioluminescent bacteria, thus allowing real-time evaluation of the development of the infection and higher compliance with the new Regulatory standards on animal use in research.
In addition to the standard animal models of infection Aptuit can help you with tailored models e.g. endocarditis, human foreign body, UTI and chronic lung infection by P. aeruginosa.